ArticleJAC-antimicrobial resistance2026
Management of infections caused by carbapenemase-producing Enterobacterales in France: a real-world study.
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Clinical outcomes of carbapenem therapy in OXA-48-producing Enterobacterales infections: a French multicentre cohort, systematic review, and meta-analysis.Emerging microbes & infections · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenemase-producing Enterobacterales (CPE) are a significant public health concern, with limited treatment options and high mortality rates. The epidemiology and management of CPE infections in France remain insufficiently documented. Objectives: To provide a multicentre snapshot of the management of CPE infections in France, assess current clinical practices and evaluate their alignment with international guidelines. Methods: We conducted a multicenter, observational, cross-sectional study across 31 French hospitals between September 2021 and March 2023. Adult patients with confirmed CPE infections were included. Clinical and microbiological data were collected retrospectively. Treatment regimens were analysed, and therapeutic appropriateness was assessed based on European and international guidelines. Results: Among 6936 screened patients, 96 met the inclusion criteria. The most frequently isolated pathogens were Conclusions: This study highlights the challenges associated with CPE infections, including high mortality and frequent inappropriate empirical therapy. Our findings emphasize the need for optimized antimicrobial stewardship and rapid microbiological diagnostics to improve patient outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.